Program
iron isomaltoside 1000
Also written as “Iron isomaltoside 1000”, “Iron isomaltoside/ferric derisomaltose” and “Monofer”.
Its studies are mostly in Anemia, Iron-Deficiency · Inflammatory Bowel Diseases · Renal Insufficiency, Chronic · Iron Deficiencies · Postpartum Hemorrhage, led by 2 companies.
Drug pageIron isomaltoside 1000: every studyAll 80 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharmacosmosits history only | 292 open or running | phase 4since Jun 13, 2017 | Sep 27, 2007 | Apr 30, 2027phase 3 · NCT05179226 |
| Sichuan Huiyu Pharmaceutical | 11 open or running | phase 1since Jul 27, 2026 | Jul 27, 2026 | none ahead |
Also a collaborator on its studies: Boji Medical Technology, BioStata, ClinStar, Laboratory Corporation of America and ClinSmart.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sichuan Huiyu Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 27, 2026First study: phase 1 study in Anemia, Iron-DeficiencyFirst studyNCT07790562 · 88 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Sichuan Huiyu Pharmaceutical leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07790562Anemia, Iron-Deficiency · China | 1 | Active, not recruiting | Sep 29, 2026 | 88 |
How it is read
Names in the registry
- “Iron isomaltoside 1000”, 6 entries
- “Iron isomaltoside/ferric derisomaltose”, 5 entries
- “Monofer”, 5 entries
- “Ferric Derisomaltose”, 2 entries
- “Iron Isomaltoside”, 2 entries
Conditions, from the studies’ own filings
- Anemia, Iron-Deficiency, 12 studies
- Inflammatory Bowel Diseases, 4 studies
- Renal Insufficiency, Chronic, 3 studies
- Iron Deficiencies, 2 studies
- Postpartum Hemorrhage, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.